Exploring the Cutting Edge

November 27, 2024

The ASX-listed Biotech set to unlock significant value

This $60m ASX-listed biotech, with a cutting-edge pipeline of transformative therapies, stands at a key inflection point for value creation.

september 20, 2024

The 7 biotech stocks (and their trials) these experts are watching right now

Hashan De Silva and Dr Bianca Ogden share the companies and trials they find interesting in the constantly innovating biotech sector.

AUGUST 6, 2024

Could this be the best market ever for healthcare investing?

KP Rx’s Hashan De Silva thinks so and is seeing enormous opportunities at attractive valuations.

JUNE 11, 2024

Aussie VC investor wants liberalisation of trans-Tasman market

Australian VC laws treats New Zealand as the 'rest of the world.' It doesn't have to be that way

MAY 14, 2024

Investor who bought Neuren at $1 a share lowers sights on $200m fund

Biotech investor Hashan De Silva is launching a new fund because he sees opportunities in medical and healthcare firms, thanks to market turmoil.

MAY 13, 2024

Be greedy when others are fearful: Why now is the time to invest in healthcare

The KP Rx Healthcare Opportunities Fund is targeting Australia & New Zealand's most innovative healthcare companies. Find out how they do it

MAY 2, 2024

This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.

The KP Rx Healthcare Opportunities Fund is targeting Australia & New Zealand's most innovative healthcare companies. Find out how they do it

MAY 1, 2024

Backed by industry titans, leveraging Australia's healthcare innovation

Early-stage healthcare investment is not for the faint-hearted (or under-researched). No one could accuse Hashan De Silva of either.

Mar 25, 2024

There is much more to come from Neuren. Following two years of substantial progress, we see significant upside from current levels.

Feb 13, 2024

Why analysts love these eight medtech stocks

The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.

Feb 12, 2024

Bupa Asia Pacific has joined the list of corporates trying their hand at venture capital investing, raising a $20 million fund with the aim of backing early stage start-ups focused on healthcare.

DEC 11, 2023

New fund targets companies battered by market doubts

A new venture capital fund aimed at funding cash-starved Australian medical, biotech and health technology start-ups has banked $40 million of a planned $200 million.

Aug 23, 2023

Technology float CurveBeam AI
graduates to ASX

CurveBeam AI has convinced fund managers to back its ASX debut with the prospect of strong sales growth in the US healthcare market predicated on more accurate osteoarthritis diagnoses.

Apr 12, 2023

Tiger cub hedge fund Karst Peak’s healthcare lead strikes out

There’s a new VC-style healthcare fund in town, as Hong Kong hedge fund Karst Peak Capital’s Sydney-based healthcare partner Hashan De Silva leaves to hang his own shingle.

MAR 13, 2023

FDA drug approval lifts biotech Neuren to $1b valuation

Biotech Neuren Pharmaceuticals surged to a $1 billion valuation on Monday after the US healthcare regulator, approved its trofinetide drug for the treatment of neurological disorder Rett syndrome.

Oct 11, 2022

Medical imaging company kicks off $15m pre-IPO

Brian Flannery-backed bone fragility imaging tech company CurveBeam AI is tapping investors for $15 million ahead of a 2023 float.

Feb 28, 2022

A de-risked biotech with 4x upside

In 2020, we acquired a major stake in a biotech company developing orphan drugs to combat this severe neurological condition.